Learn real-world evidence.

RWD Basics

Essentials for getting started with RWE.

Start with the basics

Uses in oncology

  • Trial design
  • Biomarker prioritization
  • Post marketing requirements and commitments
  • Label expansion
Start with uses in oncology

RWD basics

Real-world data is different.

The path to understanding real-world evidence starts at the point of care. Unlike data sourced from clinical trials, real-world data (RWD) are typically recorded in support of a patient’s treatment plan rather than according to a particular research protocol. This means that key insights may lie scattered across annotated radiology reports or physicians’ notes.

Without careful effort to process and verify these data, RWD may be subject to gaps and biases, rendering the data unfit for use. To succeed with RWD, researchers must first understand the quality challenges, impacts, and what measures must be taken to assure its fitness for use in the context of their research or regulatory questions.

These articles cover the fundamentals of where RWD comes from, how it is curated, processed and ultimately adopted for use by life science companies, regulators and other decision-making bodies throughout the oncology drug development lifecycle.

  • Key definitions thumbnail Key definitions thumbnail

    glossaryAsset 4 Glossary

    Key definitions

    Realizing the promise of real-world data requires alignment and consensus across many fronts, including the vocabulary of this emerging field.

    6 min read
  • Machine learning thumbnail Machine learning thumbnail

    videoAsset 7 Video

    What is machine learning's role in generating real-world data?

    Flatiron team members discuss the evolving role of machine learning and natural language processing (NLP) in real-world evidence along with appropriate applications for these technologies. Learn more about machine learning and AI.

    45 min watch
  • Endpoints Thumbnail Endpoints Thumbnail

    videoAsset 7 Video

    How are real-world endpoints derived?

    Discover how real-world endpoints are enabling new approaches and how Flatiron is partnering with regulatory and industry stakeholders to develop and evaluate them. Learn about how real-world endpoints are derived in oncology

    7 min watch
  • FDA Thumbnail FDA Thumbnail

    videoAsset 7 Video

    What's the latest FDA thinking on RWE?

    Chana Weinstock, MD, of the FDA discusses the use of real-world evidence in oncology drug approvals, the role of external control arms and how COVID-19 is impacting regulatory decision making. Watch her talk now.

    11 min watch
  • Early Adopters Thumbnail Early Adopters Thumbnail

    videoAsset 7 Video

    How early adopters are applying RWE

    Across organizations, researchers are looking to assess how RWE can support their drug development pipelines. Hear perspectives from early adopters across clinical development, regulatory and market access roles.

    57 min watch
  • HTA Thumbnail HTA Thumbnail

    videoAsset 7 Video

    An introduction to RWE for HTA and market access

    RWE is becoming a critical component of Health Technology Appraisals (HTAs) worldwide, particularly in oncology. However, questions remain about how it can be used effectively to support market access.

    57 min watch

RWE in Oncology

Using real-world evidence today.

Browse related research, case studies and other resources that highlight examples of how RWE is being used today.

Trial design

Clinical trials can provide the most definitive and robust evidence for efficacy and safety. In 2021, the average oncology phase 3 study costs nearly 250 million dollars and takes more than 3 years to read out. Today, RWD is helping to improve trial designs decisions and accelerate drug development timelines. Read this collection to learn how researchers are using RWD to predict control arm performance, establish protocols according to the latest standards of care and more.

  • expert insightAsset 6 Article For Research Partners
    Real-world data and the case of the missing deaths

    Overall survival is a key endpoint in clinical trials. But when using RWD, how is missing data addressed?

    21 min read

  • publication summaryAsset 5 Publication Summary For Research Partners
    Comparative effectiveness with RWD?

    RWD can enhance health technology appraisals by providing population-level evaluations of cancer therapies. This enables researchers to select comparator populations and inform clinical trial design.

    8 min read

  • publication summaryAsset 5 Publication Summary For Research Partners
    How rapid adoption of IO impacted outcomes in the real world

    Real-world data is curated to track novel therapies in real-time, when registries may lag for years. This makes it possible to anticipate and design trials based on actual current outcomes.

    9 min read

  • videoAsset 7 Video For Research Partners
    Use of a clinico-genomic database (CGDB) for R&D

    Combining real-world data to genomic datasets enables discovery of new prognostic biomarkers, and provides clinical evidence within unique populations needed for trial design.

    10 min watch

  • videoAsset 7 Video For Research Partners
    Impacting complex genomic/immune landscapes: Precision medicine in the real-world cancer clinic

    This talk is part of the ResearchX session: Precision Oncology: How RWD is Advancing Clinico-Genomic Research.

    14 min watch

  • podcastAsset 10 Podcast For Research Partners
    Racial and ethnic disparities: What can we learn from RWE?

    In this episode, we examine racial and ethnic disparities through the lens of oncology, real-world data and health policy.

    25 min listen

  • lockAsset 6 Methodology For Research Partners
    Statistical Biases in Real-World Data

    This article provides Flatiron research partners with a general overview of some of the common forms of statistical bias that can arise when working with RWD.

    10 min read

Have a question?

Interested in the applications of real-world data?

Fill out this form to get in touch.


Question CTA Form